Evidence map›Paper›PMID 42017387›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

QBP1 Peptide as a Potential Anti-Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study.

María M Tejero-Ojeda, Ada Bernaus Vives, Michał Wojciechowski, Dinh Quoc Huy Pham, Mateusz Chwastyk, Mario Vallejo, Anna Novials, Douglas V Laurents, Mariano Carrión-Vázquez

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

María M Tejero-OjedaInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Ada Bernaus VivesInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Michał WojciechowskiInstitute of Physics, Polish Academy of Sciences, Warsaw, Poland.
Dinh Quoc Huy PhamInstitute of Physics, Polish Academy of Sciences, Warsaw, Poland.
Mateusz ChwastykInstitute of Physics, Polish Academy of Sciences, Warsaw, Poland.
Mario VallejoCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Madrid, Spain.
Anna NovialsCentro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Madrid, Spain.
Douglas V LaurentsInstituto de Química Física Blas Cabrera, CSIC, Madrid, Spain.
Mariano Carrión-VázquezInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.ORCID https://orcid.org/0000-0001-7319-406X

Funding

Fundación General CSIC PIE 202420E226Ministerio de Ciencia e Innovación PID2020-117847RB-I00/AEI/10.13039/501100011033Ministerio de Ciencia e Innovación PID2022-137806OB-I100/AEI/10.13039/501100011033Ministerio de Ciencia e Innovación PID2024-159178OB-I00/AEI/10.13039/501100011033Spanish Large-Scale National Facility ICTS-R-LRB
6 · The paper itself

Abstract

Self-assembly and aggregation of human islet amyloid polypeptide (hIAPP, or amylin) into β-sheet-rich oligomers and fibrils have been implicated in pancreatic β-cell dysfunction and failure, contributing to the pathogenesis of type 2 diabetes (T2D). Substantial effort has gone into developing inhibitors, particularly short peptides, capable of targeting hIAPP and disrupting its amyloidogenic process, offering potential therapeutic strategies to prevent or slow T2D progression. Here, we demonstrate the effectiveness of the anti-amyloidogenic peptide QBP1 in halting the conformational conversion of hIAPP into β-structured aggregates, thereby preventing amyloidogenesis and its associated cytotoxicity. First, we evaluated the anti-amyloidogenic effects of QBP1 through cell-free in vitro aggregation experiments, including Thioflavin-T fluorescence, A11/OC dot blotting, and negative-stain electron microscopy. Circular dichroism and nuclear magnetic resonance spectroscopy corroborated that QBP1 delays hIAPP β-sheet formation and oligomerization, respectively, with an efficacy comparable to that of epigallocatechin-3-gallate. Second, we performed cell-based in vitro experiments to investigate cytoprotection in INS-1E β-cells by fusing QBP1 to the cell-penetrating peptide penetratin (Antp-QBP1). Viability assays, immunocytochemistry, and gene expression analysis showed that under amyloidogenic stress Antp-QBP1 preserves β-cell viability and metabolic homeostasis by preventing the formation of early toxic hIAPP intermediates. Finally, in silico experiments using molecular dynamics simulations revealed stable QBP1-hIAPP interactions mediated by van der Waals forces and π-H contacts involving hydrophobic and aromatic residues (e.g., W, F), supported by favorable non-polar solvation and structural complementarity. Taken together, these findings identify QBP1 as a promising candidate for strategies aimed at reducing islet amyloid burden and preserving β-cell integrity in T2D.

Indexed as

Diabetes Mellitus, Type 2Islet Amyloid PolypeptideAnimalsHumansInsulin-Secreting CellsIslet Amyloid Polypeptideaggregationamyloidogenic diseaseanti‐amyloidogenic peptidefibrilshuman islet amyloid polypeptide (hIAPP)oligomerspancreatic β‐cellsprotein misfoldingQBP1type 2 diabetes (T2D)

Identifiers

PMID42017387
PMCPMC13326014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.